Patterson Companies (NasdaqGS:PDCO) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Patterson Companies to reach your target.
Hmm, we can't give any reliable projection for Patterson Companies's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| PDCO Price (Patterson Companies stock price per share) |
$0.00 | |
| PE Ratio versus Sector | 27% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 58% lower than other Medical Distribution stocks | |
| Cash Yield | 9.25% | |
| Free Cash Flow Jitter | 207% |
No open-market insider buys or sells are recorded for the last 12 months.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
How to read this: what free cash flow is, why earnings matter.
Over the 15 fiscal years from 2009 to 2024 with positive net income, operating cash flow totaled -$979 million against net income of $2,880 million, or -0.34 times. Net income was negative in 1 of the 16 years, and those years are left out of the ratio.
In 2024, operating cash flow was -4.25 times net income, compared with 1.02 times for the earliest three years (2009 to 2011).
In 2019, capital expenditures were $60.7 million, 126.1% of operating cash flow of $48.2 million, which leaves an estimated -$12.6 million after capex. Across the 11 years with reported capex, it averaged 20.9% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
Cash conversion in 2024 was -4.25, below 0.80, so under 80% of reported net income arrived as operating cash and at least 0.25 under the 1.02 earliest three-year ratio. Gaps like this come from non-cash gains or from cash tied up in receivables, inventory or other working capital.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2009 | 200 | 124 | 32.3 | 0.62 |
| 2010 | 212 | 265 | 29.8 | 1.25 |
| 2011 | 225 | 263 | 36.8 | 1.17 |
| 2012 | 213 | 321 | 29.6 | 1.51 |
| 2013 | 210 | 299 | 22 | 1.42 |
| 2014 | 201 | 196 | 34 | 0.98 |
| 2015 | 223 | 263 | 60.7 | 1.18 |
| 2016 | 187 | 156 | 79.4 | 0.84 |
| 2017 | 171 | 163 | 47 | 0.95 |
| 2018 | 201 | 179 | 43.3 | 0.89 |
| 2019 | 83.6 | 48.2 | 60.7 | 0.58 |
| 2020 | -588 | -244 | 41.8 | n/a |
| 2021 | 156 | -731 | 25.8 | -4.68 |
| 2022 | 203 | -981 | 38.3 | -4.83 |
| 2023 | 208 | -755 | 64.2 | -3.64 |
| 2024 | 186 | -789 | 67.6 | -4.25 |
How to read this: why companies buy back shares, dividend yield explained.
Over the 10 fiscal years from 2015 to 2024 with dividend or share repurchase facts, estimated free cash flow totaled -$3,166 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In the 10 of those years with dividend payment facts, dividends paid totaled $943 million. No percentage is shown because the estimated free cash flow of those years was not positive in total. Estimated free cash flow was at least the dividends paid in 4 of those 10 years.
In 4 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $460 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2024, estimated free cash flow was -$837 million, so no percentage of it is shown. In that year dividends paid were $98.3 million.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2015 | 226 | 81.8 | 47.5 | 129 | 57.2% |
| 2016 | 111 | 90.6 | 200 | 291 | 261.3% |
| 2017 | 114 | 95.9 | 125 | 221 | 193.9% |
| 2018 | 126 | 99.2 | 87.5 | 187 | 148.1% |
| 2019 | -10 | 99.5 | n/a | 99.5 | n/a |
| 2020 | -298 | 100 | n/a | 100 | n/a |
| 2021 | -774 | 75.2 | n/a | 75.2 | n/a |
| 2022 | -1,023 | 101 | 35 | 136 | n/a |
| 2023 | -801 | 101 | 55.5 | 157 | n/a |
| 2024 | -837 | 98.3 | 230 | 328 | n/a |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $3,094 million in 2009 and $6,568 million in 2024, a compound annual growth rate of 5.1% over 15 years.
Revenue rose 1.5% from 2023 to 2024.
Our estimated free cash flow was -$837 million in 2024, a negative margin of 12.7% of revenue, meaning the estimate was below zero. In 2009 the estimated margin was 3.0%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 3,094 | 91.7 | 3.0% |
| 2010 | 3,237 | 234 | 7.2% |
| 2011 | 3,416 | 230 | 6.7% |
| 2012 | 3,536 | 289 | 8.2% |
| 2013 | 3,637 | 269 | 7.4% |
| 2014 | 3,585 | 165 | 4.6% |
| 2015 | 3,911 | 226 | 5.8% |
| 2016 | 5,387 | 111 | 2.1% |
| 2017 | 5,593 | 114 | 2.0% |
| 2018 | 5,466 | 126 | 2.3% |
| 2019 | 5,575 | -10 | -0.2% |
| 2020 | 5,490 | -298 | -5.4% |
| 2021 | 5,912 | -774 | -13.1% |
| 2022 | 6,499 | -1,023 | -15.7% |
| 2023 | 6,471 | -801 | -12.4% |
| 2024 | 6,568 | -837 | -12.7% |
How to read this: how debt and assets are compared, the current ratio.
In 2024, cash and equivalents were $114 million against total liabilities of $1,895 million, or 6.0% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 65.4% of total assets in 2024, compared with 40.5% in 2010, an increase of 24.9 percentage points.
Stockholders equity was $1,002 million in 2024, compared with $1,442 million in 2010, a fall of 30.5%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -57.7% in 2024. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 2,423 | 341 | 981 | 1,442 |
| 2011 | 2,565 | 389 | 1,004 | 1,561 |
| 2012 | 2,739 | 574 | 1,364 | 1,375 |
| 2013 | 2,682 | 505 | 1,287 | 1,394 |
| 2014 | 2,865 | 265 | 1,393 | 1,472 |
| 2015 | 2,945 | 347 | 1,431 | 1,514 |
| 2016 | 3,521 | 137 | 2,079 | 1,442 |
| 2017 | 3,508 | 95 | 2,113 | 1,394 |
| 2018 | 3,472 | 63 | 2,010 | 1,462 |
| 2019 | 3,269 | 95.6 | 1,789 | 1,481 |
| 2020 | 2,715 | 77.9 | 1,879 | 836 |
| 2021 | 2,752 | 143 | 1,787 | 965 |
| 2022 | 2,742 | 142 | 1,699 | 1,043 |
| 2023 | 2,879 | 160 | 1,761 | 1,119 |
| 2024 | 2,897 | 114 | 1,895 | 1,002 |
We do not estimate a fair value for Patterson Companies while its free cash flow growth is not positive, so there is no value comparison here.
Free cash flow was positive in 10 out of 16 reported years for Patterson Companies, using only its current SEC filer.
Free cash flow is volatile from year to year, with a variability measure of 207%.
Before you act on any of this, read what a margin of safety means and check the company's own filings.
No dividend yield is recorded for Patterson Companies in our data.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 27% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 58% below the average for stocks in the Medical Distribution industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Medical Distribution industry, the ones closest in market capitalization to Patterson Companies, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Patterson Companies (PDCO) | - | - | - | 9.3% | - |
| Herbalife Nutrition Ltd. (HLF) | 1,629 | 9.1 | - | 39.8% | 97% below |
| Henry Schein (HSIC) | 9,232 | 22.9 | - | 7.3% | 44% below |
| McKesson Corporation (MCK) | 123,473 | 27.6 | 0.3% | 3.3% | 30% below |
| Nu Skin Enterprises (NUS) | 185 | - | 6.4% | 182.1% | 98% below |
| SiteOne Landscape Supply (SITE) | 4,646 | 28.4 | - | - | 180% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 891024.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: PDCO annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Patterson Companies have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to PDCO: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market